Safety, efficacy and predictors of local recurrence after percutaneous radiofrequency ablation of biopsy-proven renal cell carcinoma
- 258 Downloads
To evaluate the safety and efficacy of percutaneous radiofrequency ablation (RFA) for localised renal cell carcinoma (RCC) and examine potential associations between age, gender, tumour size, location, chronic kidney disease, comorbidities, learning curve and local recurrence.
We retrospectively analysed survival outcomes for patients with biopsy-proven RCC treated by RFA at Westmead Hospital. Complication data were gathered from all patients that underwent renal RFA. 3 and 5 year local recurrence-free (RFS), disease-free (DFS) and overall survival (OS) outcomes were reported. Univariate and multivariate analysis was used to examine each potential predictor.
A total of 168 patients were eligible for the study. Forty-eight patients with biopsy-proven RCC had minimum 3-year follow-up. Our complication rate was 1.2 % (2/168) and local recurrence rate 10.4 % (5/48). Five-year RFS, DFS and OS were 86.8, 82.3 and 92.6 % on a median 4.1-year follow-up (IQR 3.4–4.9). None of the patient or tumour-specific characteristics were associated with RFS.
Radiofrequency ablation performed at our centre was a safe and effective procedure with low complication rates and durable RFS. Tumour characteristics, comorbidities and learning curve were not associated with local recurrence.
KeywordsPercutaneous ablation Radiofrequency ablation Carcinoma, renal cell Neoplasm recurrence, local Oncological outcomes
We thank Ms. Pamela Dougan for her invaluable efforts as data administrator, Ms. Karen Byth for her assistance with statistical analysis and Dr. Philip Vladica for acting as the guarantor for this paper.
Compliance with ethical standards
Conflict of interest
Michael Su, Fatima Memon, Howard Lau, Andrew Brooks, Manish Patel, Henry Woo, Simon Bariol and Philip Vladica declares that they have no conflict of interest.
This study did not receive any funding.
All procedures performed in the study involving human participants were in accordance with the ethical standards of the institutional human research ethics committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 5.Wehrenberg-Klee E, Clark TWI, Malkowicz SB, Soulen MC, Wein AJ, Mondschein JI, Van Arsdalen K, Guzzo TJ, Stavropoulos SW (2012) Impact on renal function of percutaneous thermal ablation of renal masses in patients with preexisting chronic kidney disease. J Vasc Interv Radiol 23:41–45CrossRefPubMedGoogle Scholar
- 7.Atwell TD, Carter RE, Schmit GD, Carr CM, Boorjian SA, Curry TB, Thompson RH, Kurup AN, Weisbrod AJ, Chow GK, Leibovich BC, Callstrom MR, Patterson DE (2012) Complications following 573 percutaneous renal radiofrequency and cryoablation procedures. J Vasc Interv Radiol 23:48–54CrossRefPubMedGoogle Scholar
- 15.Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, de Santibanes E, Pekolj J, Slankamenac K, Bassi C, Graf R, Vonlanthen R, Padbury R, Cameron JL, Makuuchi M (2009) The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 250:187–196CrossRefPubMedGoogle Scholar
- 22.Campbell SC, Novick AC, Belldegrun A, Blute ML, Chow GK, Derweesh IH, Faraday MM, Kaouk JH, Leveillee RJ, Matin SF, Russo P, Uzzo RG, Practice Guidelines Committee of the American Urological A (2009) Guideline for management of the clinical T1 renal mass. J Urol 182:1271–1279CrossRefPubMedGoogle Scholar